カテゴリ： GlobalData, アメリカ, 企業調査

Foundation Medicine Inc (FMI)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Foundation Medicine Inc (FMI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014170
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：60
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd is a healthcare products provider that offers cancer care solutions. The company offers molecular information and cancer research programs. It offers clinical products which include FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas and others. It also offers additional materials, services, and real-time data through its technology products. The company partners with biotech and pharmaceutical companies to develop targeted cancer therapies and active clinical trials. Foundation Medicine is headquartered in Cambridge, Massachusetts, the US.

Foundation Medicine Inc (FMI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 16
Partnerships 17
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 17
Epizyme Enters into Agreement with Foundation Medicine 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Partners with AstraZeneca 20
Foundation Medicine Enters into Agreement with Mirati Therapeutics 21
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 22
Roche Amends R&D Agreement with Foundation Medicine 23
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 24
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 25
Foundation Medicine Expands Co-Development Agreement With Novartis 26
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 27
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 28
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Equity Offering 31
Foundation Medicine Raises USD250 Million in Private Placement of Shares 31
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 32
Foundation Medicine Completes IPO Of Shares For US$122 Million 33
Acquisition 34
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 34
Foundation Medicine Inc – Key Competitors 36
Foundation Medicine Inc – Key Employees 37
Foundation Medicine Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Nov 01, 2017: Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights 39
Aug 01, 2017: Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights 40
May 09, 2017: Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights 42
Feb 22, 2017: Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook 44
Jan 09, 2017: Foundation Medicine Reports Preliminary 2016 Results 45
Nov 02, 2016: Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights 47
Aug 02, 2016: Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights 49
May 03, 2016: Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights 51
Feb 23, 2016: Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook 52
Jan 11, 2016: Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay 53
Corporate Communications 54
Oct 10, 2017: Foundation Medicine Appoints Tom Civik as Chief Commercial Officer 54
Jan 06, 2017: Foundation Medicine Announces Executive Leadership Transition 55
Oct 27, 2016: Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors 56
Product News 57
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 57
Other Significant Developments 59
Feb 25, 2016: Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 16
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 17
Epizyme Enters into Agreement with Foundation Medicine 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Partners with AstraZeneca 20
Foundation Medicine Enters into Agreement with Mirati Therapeutics 21
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 22
Roche Amends R&D Agreement with Foundation Medicine 23
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 24
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 25
Foundation Medicine Expands Co-Development Agreement With Novartis 26
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 27
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 28
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Foundation Medicine Raises USD250 Million in Private Placement of Shares 31
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 32
Foundation Medicine Completes IPO Of Shares For US$122 Million 33
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 34
Foundation Medicine Inc, Key Competitors 36
Foundation Medicine Inc, Key Employees 37
Foundation Medicine Inc, Other Locations 38

★海外企業調査レポート[Foundation Medicine Inc (FMI)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Mizuho Trust & Banking Co Ltd：企業の戦略・SWOT・財務情報
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Boehringer Ingelheim GmbH-製薬・医療分野：企業M&A・提携分析
    Summary Boehringer Ingelheim GmbH (Boehringer), a subsidiary of C. H. Boehringer Sohn AG & Co KG is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer healt …
  • TAS S.p.A. (TAS)：企業の財務・戦略的SWOT分析
    TAS S.p.A. (TAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • King Country Energy Ltd：企業の戦略的SWOT分析
    King Country Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Rheinmetall AG：企業の戦略・SWOT・財務情報
    Rheinmetall AG - Strategy, SWOT and Corporate Finance Report Summary Rheinmetall AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Aceto Corp (ACET)：企業の財務・戦略的SWOT分析
    Aceto Corp (ACET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PharmaCyte Biotech Inc (PMCB)-医療機器分野：企業M&A・提携分析
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company’s technology is used for the treatment of advanced and inoperable pancreatic cancer, and diabetes. It develops …
  • Quest Diagnostics Incorporated：企業のM&A・事業提携・投資動向
    Quest Diagnostics Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Quest Diagnostics Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Inhalation Sciences Sweden AB-医療機器分野：企業M&A・提携分析
    Summary Inhalation Sciences Sweden AB (ISAB) develops and sells innovative laboratory equipment for inhalation research and provides drug development services. The company's product portfolio includes PreciseInhale and LaminarPace systems. It sells tools and services which accelerates the drug disco …
  • TIS Inc (3626)：企業の財務・戦略的SWOT分析
    TIS Inc (3626) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Novolex Holdings, Inc.：企業の戦略的SWOT分析
    Novolex Holdings, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Mega Uranium Ltd. (MGA)：企業の財務・戦略的SWOT分析
    Mega Uranium Ltd. (MGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Braeburn Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析
    Summary Braeburn Pharmaceuticals Inc (Braeburn), a subsidiary of Apple Tree Partners is a pharmaceutical company that develops novel and long-acting implantable and injectable treatments.The company’s product pipeline includes Probuphine, CAM2038, BB-0417, BB-0817, BB-1216. Its Probuphine, is a a si …
  • Evofem Biosciences Inc (EVFM)：製薬・医療：M&Aディール及び事業提携情報
    Summary Evofem Biosciences Inc (Evofem) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes reproductive and contraceptive care products for women. The company’s lead product candidate includes Amphora, a non-hormonal vaginal contraceptive gel for the prevention …
  • Asseco Poland S.A.：企業のM&A・事業提携・投資動向
    Asseco Poland S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Asseco Poland S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • IntelGenx Corp：企業のM&A・事業提携・投資動向
    IntelGenx Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IntelGenx Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • BAE Systems Inc：企業の戦略・SWOT・財務情報
    BAE Systems Inc - Strategy, SWOT and Corporate Finance Report Summary BAE Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Wilmar International Ltd (F34)：企業の財務・戦略的SWOT分析
    Wilmar International Ltd (F34) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Correvio Pharma Corp (CORV)：企業の財務・戦略的SWOT分析
    Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Sorgenia SpA：電力：M&Aディール及び事業提携情報
    Summary Sorgenia SpA (Sorgenia) is an electricity generator and energy utilities company. The company operates in the energy and natural gas sector. It produces, imports, and sells electricity and gas. The company also offers various integrated power saving equipment and services. Sorgenia is a grou …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆